Utility of real-time antifungal susceptibility testing for fluconazole in the treatment of candidemia

被引:24
作者
Baddley, JW [1 ]
Patel, M
Jones, M
Cloud, G
Smith, AC
Moser, SA
机构
[1] Univ Alabama Birmingham, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA
[2] Birmingham Vet Adm Med Ctr, Birmingham, AL USA
[3] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA
关键词
antifungal susceptibility; Candida; candidemia;
D O I
10.1016/j.diagmicrobio.2004.06.004
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Our study prospectively examined the use of real-time antifungal susceptibility testing among 119 patients with candidemia at a large tertiary university medical center over a 1-year period. Susceptibility results to fluconazole were reported to physicians a mean of 5.1 days after the initial positive blood culture for Candida. Physicians believed that receiving antifungal susceptibility testing results was helpful and not infrequently altered therapy on the basis of results. Outcomes, including mortality and resolution of infection, among 20 (17%) patients with fluconazole-resistant and fluconazole-susceptible dose-dependent isolates were relatively poor compared to those among patients with fluconazole-susceptible isolates, but probably reflect severity of illness. Routine susceptibility testing as an adjunct to the treatment of candidemia has significant potential and warrants further study. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:119 / 124
页数:6
相关论文
共 23 条
  • [1] The epidemiology of hematogenous candidiasis caused by different Candida species
    AbiSaid, D
    Anaissie, E
    Uzun, O
    Raad, I
    Pinzcowski, H
    Vartivarian, S
    [J]. CLINICAL INFECTIOUS DISEASES, 1997, 24 (06) : 1122 - 1128
  • [2] [Anonymous], 2002, M27A2 CLSI
  • [3] Candidemia in a tertiary care cancer center - In vitro susceptibility and its association with outcome of initial antifungal therapy
    Antoniadou, A
    Torres, HA
    Lewis, RE
    Thornby, J
    Bodey, GP
    Tarrand, JJ
    Han, XY
    Rolston, KVI
    Safdar, A
    Raad, II
    Kontoyiannis, DP
    [J]. MEDICINE, 2003, 82 (05) : 309 - 321
  • [4] Trends in frequency and susceptibilities of Candida glabrata bloodstream isolates at a University Hospital
    Braddley, JW
    Smith, AM
    Moser, SA
    Pappas, PG
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2001, 39 (03) : 199 - 201
  • [5] Trends in antifungal susceptibility among Swedish Candida species bloodstream isolates from 1994 to 1998:: Comparison of the E-test and the Sensititre YeastOne Colorimetric Antifungal Panel with the NCCLS M27-A reference method
    Chryssanthou, E
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (11) : 4181 - 4183
  • [6] CLANCY CJ, 1998, 36 ANN M INF DIS SOC
  • [7] Real-time antifungal susceptibility screening aids management of invasive yeast infections in immunocompromised patients
    Hadley, S
    Martinez, JA
    McDermott, L
    Rapino, B
    Snydman, DR
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 (02) : 415 - 419
  • [8] The epidemiology of candidemia in two United States cities: Results of a population-based active surveillance
    Kao, AS
    Brandt, ME
    Pruitt, WR
    Conn, LA
    Perkins, BA
    Stephens, DS
    Baughman, WS
    Reingold, AL
    Rothrock, GA
    Pfaller, MA
    Pinner, RW
    Hajjeh, RA
    [J]. CLINICAL INFECTIOUS DISEASES, 1999, 29 (05) : 1164 - 1170
  • [9] Kovacicova G, 2000, J Infect Chemother, V6, P216, DOI 10.1007/s101560070006
  • [10] Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole
    Lee, SC
    Fung, CP
    Huang, JS
    Tsai, CJ
    Chen, KS
    Chen, HY
    Lee, N
    See, LC
    Shieh, WB
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (10) : 2715 - 2718